Cargando…

Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

The trifunctional antibody catumaxomab is a targeted immunotherapy for the intraperitoneal treatment of malignant ascites. In a Phase II/III trial in cancer patients (n = 258) with malignant ascites, catumaxomab showed a clear clinical benefit vs. paracentesis and had an acceptable safety profile. H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ott, Marion G, Marmé, Frederik, Moldenhauer, Gerhard, Lindhofer, Horst, Hennig, Michael, Spannagl, Rolf, Essing, Mirko M, Linke, Rolf, Seimetz, Diane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Subscription Services, Inc., A Wiley Company 2012
Materias:	Cancer Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415680/ https://www.ncbi.nlm.nih.gov/pubmed/21702044 http://dx.doi.org/10.1002/ijc.26258

Ejemplares similares

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
por: Heiss, Markus M, et al.
Publicado: (2010)

Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab(®))
por: Seimetz, Diane
Publicado: (2011)

Review of catumaxomab in the treatment of malignant ascites
por: Sebastian, Martin
Publicado: (2010)

Palliative treatment of malignant ascites: profile of catumaxomab
por: Ammouri, Lila, et al.
Publicado: (2010)

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
por: Ruf, Peter, et al.
Publicado: (2010)

First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity
por: Ruf, Peter, et al.
Publicado: (2021)

Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro
por: Seeber, Andreas, et al.
Publicado: (2015)

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial
por: Tesch, Hans, et al.
Publicado: (2018)

Antitumor activity of an anti‐CD98 antibody
por: Hayes, Gregory M., et al.
Publicado: (2015)

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
por: Knödler, Maren, et al.
Publicado: (2018)

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
por: Seeber, Andreas, et al.
Publicado: (2015)

Prolonged expression of the γ-H2AX DNA repair biomarker correlates with excess acute and chronic toxicity from radiotherapy treatment
por: Bourton, Emma C, et al.
Publicado: (2011)

A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo
por: Kulcsár, Gyula, et al.
Publicado: (2013)

Mangrove dolabrane‐type of diterpenes tagalsins suppresses tumor growth via ROS‐mediated apoptosis and ATM/ATR–Chk1/Chk2‐regulated cell cycle arrest
por: Neumann, Jennifer, et al.
Publicado: (2015)

Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis
por: Lacroix, Jeannine, et al.
Publicado: (2014)

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
por: Schmieder, Roberta, et al.
Publicado: (2014)

Triptolide reverses hypoxia-induced epithelial–mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation
por: Liu, Li, et al.
Publicado: (2014)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer
por: Poff, AM, et al.
Publicado: (2014)

Selective depletion of tumor neovasculature by microbubble destruction with appropriate ultrasound pressure
por: Wang, Junfen, et al.
Publicado: (2015)

Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts
por: Koga, Yoshikatsu, et al.
Publicado: (2015)

Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab
por: Goéré, Diane, et al.
Publicado: (2014)

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone
por: Wimberger, P., et al.
Publicado: (2012)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

Ovarian Cancer–Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
por: Schouten, Philip C., et al.
Publicado: (2021)

P18. The tumour leukocyte infiltrate is the key predictor for therapeutic response to catumaxomab therapy
por: Weiler, K, et al.
Publicado: (2014)

Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report
por: Bezan, Angelika, et al.
Publicado: (2013)

The unfavorable effects of COVID‐19 on Dutch advanced melanoma care
por: van Not, Olivier J., et al.
Publicado: (2021)

The pivotal role of DNA methylation in the radio‐sensitivity of tumor radiotherapy
por: Zhu, Xueru, et al.
Publicado: (2018)

Sorafenib with ASC‐J9(®) synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals
por: Xu, Junjie, et al.
Publicado: (2016)

Use of thermo‐coagulation as an alternative treatment modality in a ‘screen‐and‐treat’ programme of cervical screening in rural Malawi
por: Campbell, Christine, et al.
Publicado: (2016)

Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma
por: Wilkinson, Michelle J., et al.
Publicado: (2016)

Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
por: Pan, Zhenyu, et al.
Publicado: (2016)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
por: Kato, Junko, et al.
Publicado: (2016)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
por: Eng, Cathy, et al.
Publicado: (2016)

Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo
por: Voloshin, Tali, et al.
Publicado: (2016)

Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women
por: Gultekin, Murat, et al.
Publicado: (2017)

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
por: Luo, Yong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4rake0ocf4o7p9nod9ersihirm